We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Microsatellite Instability Assay Validated for Cancer Studies

By LabMedica International staff writers
Posted on 20 Nov 2018
Microsatellite instability (MSI) occurs when mismatch repair proteins (MMR) fail to fix a DNA replication error, leading to frame-shift mutations in a person's genetic code and non-functioning proteins. More...
MSI has acted as a strong marker for genetic conditions such as Lynch syndrome that can lead to a variety of cancers.

Multiple companies have developed MSI assays to detect a variety of early-stage cancers. The US Food and Drug Administration (FDA Silver Springs, MD, USA) has granted Breakthrough Device designation to two companies for their existing next-generation sequencing RUO liquid biopsy assays to include MSI detection. Under the program, the FDA works with a test developer to reduce the time and cost from development to approval.

A scientific team from Memorial Sloan Kettering Cancer Center (MSKCC, New York, NY, USA) recently presented unpublished validation studies on the Idylla microsatellite instability assay demonstrating its ability to detect traces of tumor mutations in a variety of cancers such as endometrial and colorectal carcinoma.

The MSKCC team validated the use of the Idylla MSI assay for ultra-rapid assessment of MSI status on formalin-fixed, paraffin-embedded (FFPE) tissue sections without the need for prior DNA extraction or concurrent testing with a normal control. The team examined 52 tumor samples: 38 FFPE and 14 extracted DNA, with known MSI status and ran them on the Idylla MSI assay. The team labeled the samples based on the presence of instability in the seven markers: if the samples had two or more unstable biomarkers, they were considered MSI-H; if the samples had fewer than two unstable biomarkers, they were considered MSI stable (MSS).

The team then compared the results to previously determined MSI status based on NGS data generated by MSK-IMPACT, a MSI-PCR tool and an MMR immunohistochemistry assay. The team found concordant results for 24 of 25 MSI-H and 26 of 27 of the MSS cases between Biocartis and Promega's assays, for an overall concordance of 96%. The scientists required four minutes of hands-on time to run the assay, with about 150 minutes from setup to report generation. The investigators concluded that the Idylla MSI test is a simple and fully automated solution for MSI status determination, providing quick results that are concordant with other MSI testing approaches. The study was presented at the Association for Molecular Pathology annual meeting held November 1-3, 2018, in San Antonio, TX, USA.

Related Links:
US Food and Drug Administration
Memorial Sloan Kettering Cancer Center


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.